EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Molecular impact of antisense oligonucleotide therapy in C9orf72-associated ALS

Zachary T McEachin, Mingee Chung, Sabrina A Stratton, Changhee Han, Woo Jae Kim, Udit Sheth, Eleanor V Thomas, Ethan Issenberg, Tanvi Kamra, Paola Merino, Yona Levites, Nisha Raj und 21 weitere

Cell · 2025-11 · 188 (23) · 6424-6435.e17

DOI: 10.1016/j.cell.2025.07.045 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell, 2025-11. Verfasst von Zachary T McEachin und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Genetics, Emory University, Atlanta, GA 30322, USA; Department of Cell Biology, Emory University, Atlanta, GA 30322, USA; Laborat…. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, C9orf72 Protein, Oligonucleotides, Antisense. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NINDS NIH HHS, National Institute on Aging.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

C9orf72-associated amyotrophic lateral sclerosis (c9ALS) is caused by an intronic G4C2 repeat expansion that leads to toxic RNA transcripts and dipeptide repeat proteins (DPRs). A clinical trial using the antisense oligonucleotide (ASO) BIIB078 to target these transcripts was discontinued after failing to provide clinical benefit. Here, we determine the extent of target engagement in the central nervous system (CNS) and elucidate pharmacodynamic cerebrospinal fluid (CSF) biomarkers following treatment. CSF from BIIB078-treated cases showed reduced DPRs and sustained increases in inflammatory biomarkers, including C-C motif chemokine ligand 26 (CCL26). BIIB078 was widely distributed in postmortem CNS tissue; however, DPRs and phosphorylated TDP-43 remained abundant. Proteomic signatures in c9ALS spinal cord were not altered with treatment, although a distinct increase in RNase T2 abundance that correlated with BIIB078 concentration was observed. Thus, despite widespread distribution, BIIB078 did not significantly impact key CNS pathologies, emphasizing the need to identify pharmacodynamic biomarkers that reflect disease-relevant neuropathological changes in response to ASO therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisC9orf72 ProteinOligonucleotides, AntisenseHumansMaleFemaleSpinal CordMiddle AgedAgedBiomarkersDNA-Binding ProteinsCentral Nervous System

Stichwörter der Autor:innen

BIIB078C9orf72NULISATDP-43amyotrophic lateral sclerosisantisense oligonucleotidesdipeptide repeat proteinsproteomics

Substanzen

C9orf72 ProteinOligonucleotides, AntisenseC9orf72 protein, humanBiomarkersDNA-Binding ProteinsTARDBP protein, human

Autor:innen und Institutionen

  • Department of Human Genetics, Emory University, Atlanta, GA 30322, USA; Department of Cell Biology, Emory University, Atlanta, GA 30322, USA; Laboratory for Translational Cell Biology, Emory University, Atlanta, GA 3032…
  • Department of Human Genetics, Emory University, Atlanta, GA 30322, USA; Laboratory for Translational Cell Biology, Emory University, Atlanta, GA 30322, USA.
  • Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Jacksonville, FL 32224, USA; Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.
  • Goizueta Brain Health Institute Center for Neurodegenerative Diseases, Emory University, Atlanta, GA 30322, USA; Department of Neurology, Emory University, Atlanta, GA 30322, USA.
  • Goizueta Brain Health Institute Center for Neurodegenerative Diseases, Emory University, Atlanta, GA 30322, USA; Department of Pharmacology & Chemical Biology, Emory University, Atlanta, GA 30322, USA.
  • Goizueta Brain Health Institute Center for Neurodegenerative Diseases, Emory University, Atlanta, GA 30322, USA; Department of Biochemistry, Emory University, Atlanta, GA 30322, USA.

Förderung

  • NIA NIH HHS
  • NINDS NIH HHS
  • National Institute on Aging
  • Association for Frontotemporal Degeneration
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

McEachin, Z. T., Chung, M., Stratton, S. A., Han, C., Kim, W. J., Sheth, U., Thomas, E. V., Issenberg, E., Kamra, T., Merino, P., Levites, Y., Raj, N., Dammer, E. B., Duong, D. M., Ping, L., Shantaraman, A., Trautwig, A. N., Gadhavi, J., Assefa, E., …, & Glass, J. D. (2025). Molecular impact of antisense oligonucleotide therapy in C9orf72-associated ALS. Cell, 188(23), 6424-6435.e17. https://doi.org/10.1016/j.cell.2025.07.045

Vancouver

McEachin ZT, Chung M, Stratton SA, Han C, Kim WJ, Sheth U, et al. Molecular impact of antisense oligonucleotide therapy in C9orf72-associated ALS. Cell. 2025;188(23):6424-6435.e17. doi:10.1016/j.cell.2025.07.045

BibTeX
@article{McEachin2025,
  author = {McEachin, Zachary T and Chung, Mingee and Stratton, Sabrina A and Han, Changhee and Kim, Woo Jae and Sheth, Udit and Thomas, Eleanor V and Issenberg, Ethan and Kamra, Tanvi and Merino, Paola and Levites, Yona and Raj, Nisha and Dammer, Eric B and Duong, Duc M and Ping, Lingyan and Shantaraman, Anantharaman and Trautwig, Adam N and Gadhavi, Joshna and Assefa, Ezana and Gearing, Marla and Kelly, Kaylor M and Roemer, Shanu F and DeTure, Michael and Asress, Seneshaw and Kukar, Thomas and Fournier, Christina and Dickson, Dennis W and Petrucelli, Leonard and Golde, Todd E and Oskarsson, Björn and Gendron, Tania F and Seyfried, Nicholas T and Glass, Jonathan D},
  title = {Molecular impact of antisense oligonucleotide therapy in C9orf72-associated ALS},
  journal = {Cell},
  year = {2025},
  volume = {188},
  number = {23},
  pages = {6424--6435.e17},
  doi = {10.1016/j.cell.2025.07.045}
}
Kostenlos starten →